tbuckley/cabot-search huggingface dataset:
Synergistic antitumor activity by combination with chemotherapeutic agents and radiation against gastric cancer cell lines with increased apoptotic induction
Authors: Tsuyoshi Kiyota, Yoshiro Saikawa, Rieko Nakamura, Masashi Yoshida, Tetsuro Kubota, Koichiro Kumai, Masaki Kitajima
Journal: Cancer Research (2006)

584  [Background] Recently, chemoradiotherapy has been reported to show more effective outcome than chemotherapy alone in the treatment of gastrointestinal cancer patients, however, few scientific evidence to support the effectiveness of chemoradiotherapy have been clarified at present. [Purpose] In the study, we are to clarify the antitumor activity by combination with chemotherapeutic agents and radiation, using in vitro system of gastric cancer cell lines. [Materials and Methods] 1) Human gastric cancer cell lines, MKN-45/MKN-74/TMK-1, were utilized in order to investigate the combination effect by chemoradiation using cisplatin (CDDP) or 5-fluorouracil (5-FU). The cell lines were exposed with various concentrations of CDDP / 5-FU for 24 hour followed by radiation (0-12Gy). Cell counting was triplicated to evaluate antitumor activity, analyzing synergistic/antagonistic combination effect with the chemotherapeutic agents and radiation using isobologram. 2) Apoptotic inductions after exposure of radiation 0/4 Gy followed by exposure of CDDP 3 μg/ml/5-FU 2 μg/ml were evaluated in MKN-45 by photometric enzyme immunoassay for the quantitative in vitro determination of cytoplasmic histone-associated DNA fragments (Cell Death Detection ELISA PLUS, Roche Applied Science, Mannheim, Germany). [Results] 1) a) In MKN-45, Inhibition rates (IRs) of CDDP 0/3/10 μg/ml without/with radiation were 0/43/65% (0 Gy), 35/60/74% (2 Gy), 43/78/91% (6Gy), respectively, evaluated as synergistic effect. IRs of 5-FU 0/1/3 μg/ml without/with radiation were 0/61/78% (0 Gy), 18/64/88% (2 Gy), 82/91/93 % (6 Gy), evaluated as synergistic effect. b) In MKN-74, IRs of CDDP 0/3/10 μg/ml without/with radiation were 0/56/78% (0 Gy), 51/73/83% (2 Gy), 72/89/92% (6 Gy), evaluated as synergistic effect. IRs of 5-FU 0/3/10 μg/ml without/with radiation were 0/45/63% (0 Gy), 24/56/71% (2 Gy), 57/72/73 % (6 Gy), evaluated as additive effect. c) In TMK-1, IRs of CDDP 0/1/3 μg/ml without/with radiation were 0/46/74% (0 Gy), 20/75/82% (2 Gy), 57/89/95% (6 Gy), evaluated as synergistic. IRs of 5-FU 0/10/30 μg/ml without/with radiation were 0/61/70% (0 Gy), 36/74/85% (6 Gy), 70/82/90 % (10 Gy), evaluated as synergistic. 2) Apoptosis Enrichment Factors by radiation 0/4 Gy without/with drug were 1/1.16 (without drug), 0.92/1.24 (with CDDP 3 μg/ml), 0.95/1.51 (with 5-FU 2 μg/ml), suggesting that apoptosis was induced by additional radiation to chemotherapeutic agents, while chemotherapeutic agent alone did not showed apoptosis at the concentration. [Conclusion] Radiation will be an effective tool, enhancing antitumor activity of chemotherapeutic agents against gastric cancer cell lines in vitro. In addition, apoptotic induction was observed by means of additional radiation to chemotherapy, suggesting one of mechanism of synergy in antitumor activity by chemoradiation.
Herpes—A Not So Simple(x) History
Authors: Arvin Ighani
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
AB1045 CLINICAL, ANALYTICAL AND RADIOLOGICAL CHARACTERISTICS OF A COHORT OF PATIENTS WITH SARCOIDOSIS.
Authors: I. Madroñal García, C. Aguilera Cros, L. Mendez Diaz
Journal: Annals of the Rheumatic Diseases (2020)

Background: Sarcoidosis is a systemic disease whose etiology is unknown. It is characterized by the formation of granulomas in any tissue of the organism. Ganglionic, pulmonary and cutaneus involvement is the most prevalent. Objectives: Describe clinical characteristics of a cohort of patients with sarcoidosis diagnosed. Define the association between the ACE’s number at diagnosis, radiological lung stage, treatment and course of disease. Evaluate if the extrapulmonary involvement is related to the course of the disease. Methods: Descriptive retrospective study of patients with S diagnosis treated in our Hospital in 2019. Data were obtained by reviewing medical records. Chi-square tests and parametric tests have been used to establish the differences described in the objectives. Results: 102 patients diagnosed with sarcoidosis have been included, (51% females) with an average age of 56±11 years. Suspected diagnosis at the onset of disease was S in 70.6% of patients, followed by suspected lymphoma (20.6%). The average time for the definitive diagnosis of S was 9.5 months. 70.6% of the patients had elevated ACE titles at the beginning. Regarding the clinical manifestations, 18.6% of the patients presented fever at the beginning and 66.7% extrathoracic clinical manifestations. 72.5% have lymph node adenopathies, and in 91% there is thoracic involvement (the most frequent pulmonary stage is stage II). A biopsy was performed in 84.3% of the patients, the lung biopsy being the most performed (52.3%). 88.2% of patients received corticosteroid treatment at the onset of the disease (currently under treatment with corticosteroids 37.3%). 50% of patients are treated with immunosuppressants, Methotrexate was the most used. 5 patients are treated with biological therapy (AntiTNF). Regarding the course of the disease, 51% of the patients have a chronic course, 45.1% are in remission and 3.9% have suffered a relapse of the disease. In this study, no significant relationship was found between the ACE values at the onset of the disease, the pulmonary stage and the course of the disease. According to our data, patients presenting with extrathoracic clinical manifestations need more frequently corticosteroid treatment (p = 0.017) and immunosuppressive treatment (p = 0.001) with respect to patients who do not have an extrathoracic clinic. In addition, patients with an extrathoracic clinic present more frequently a chronic course of the disease than those who do not (p = 0.019). Conclusion: The results described in this study are similar to those found in the literature. The differences found can be explained because patients presenting with extrathoracic clinical manifestations have a more complicated management and need more treatment than those with only pulmonary involvement, even patients with radiological stage I do not usually need treatment, only surveillance. Disclosure of Interests: None declared
SP0142 Foreplay and finale: factors affecting fertility, birth and lactation in rheumatoid arthritis patients. clinical case
Authors: P Nero
Journal: Annals of the Rheumatic Diseases (2017)

We present the clinical case of a 38 year old woman diagnosed with rheumatoid arthritis at the age of 32. She went into remission of her disease during treatment with subcutaneous methotrexate (25 mg/week) for 2 years. She decided to become pregnant and stoped treatment. RA relapses 4 months later and she has no response to classic DMARD9s (sulphassalazine and hydroxychloroquine) and starts etanercept (50mg/week). She gets pregnant and achieves remission at week 16 of her pregnancy. At week 36 she is still in remission and stops etanercept. 2 months after giving birth the disease relapses but she wants to breastfeed and would like to restart etanercept. We agreed and 3 months after restarting anti-TNF RA is again in remission. In January 2017 her RA is inremission for 15 months and keeps her medication with etanercept every other week because she plans another pregnancy. <h3>Disclosure of Interest</h3> None declared
Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention
Authors: Delbert G. Robinson, Nina R. Schooler, Christoph U. Correll, Majnu John, Benji T. Kurian, Patricia Marcy, Alexander L. Miller, Ronny Pipes, Madhukar H. Trivedi, John M. Kane
Journal: American Journal of Psychiatry (2017)

Objective: The Recovery After an Initial Schizophrenia Episode–Early Treatment Program compared NAVIGATE, a comprehensive program for first-episode psychosis, to clinician-choice community care over 2 years. Quality of life and psychotic and depressive symptom outcomes were found to be better with NAVIGATE. Compared with previous comprehensive first-episode psychosis interventions, NAVIGATE medication treatment included unique elements of detailed first-episode-specific psychotropic medication guidelines and a computerized decision support system to facilitate shared decision making regarding prescriptions. In the present study, the authors compared NAVIGATE and community care on the psychotropic medications prescribed, side effects experienced, metabolic outcomes, and scores on the Adherence Estimator scale, which assesses beliefs related to nonadherence. Method: Prescription data were obtained monthly. At baseline and at 3, 6, 12, 18, and 24 months, participants reported whether they were experiencing any of 21 common antipsychotic side effects, vital signs were obtained, fasting blood samples were collected, and the Adherence Estimator scale was completed. Results: Over the 2-year study period, compared with the 181 community care participants, the 223 NAVIGATE participants had more medication visits, were more likely to receive a prescription for an antipsychotic and more likely to receive one conforming to NAVIGATE prescribing principles, and were less likely to receive a prescription for an antidepressant. NAVIGATE participants experienced fewer side effects and gained less weight; other vital signs and cardiometabolic laboratory findings did not differ between groups. Adherence Estimator scores improved in the NAVIGATE group but not in the community care group. Conclusions: As part of comprehensive care services, medication prescription can be optimized for first-episode psychosis, contributing to better outcomes with a lower side effect burden than standard care.
FRI0516 Assessment of disease remission by power doppler ultrasonography in patients with psoriatic arthritis
Authors: S Monov, R Shumnalieva, D Monova, A Kopchev
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Treatment strategies nowadays are targeting clinical remission or low disease activity. In some patients with psoriatic arthritis (PsA) clinical findings defer from the ultrasonographic evidence of inflammation which raise the need for revising the remission criteria in the clinical practice. <h3>Objectives</h3> The aim of our study was to estimate the presence of subclinical synovitis by power Doppler ultrasonography (PDUS) in PsA patients, who were considered as being in clinical remission defined by DAS28-ESR (Disease activity score of 28 joints – erythrocyte sedimentation rate) for at least 6 months during the treatment course. <h3>Methods</h3> 64 PsA patients in clinical remission based on DAS28 – ESR &lt;2.6 were included in the study. The patients were examined by two independent rheumatologists. The affected joints were assessed by PDUS (MyLab 60, Esaote) for the presence of synovial hypertrophy (SH) and synovitis scored from 0 to 3 based on the presence and intensity of PD signal. Disease activity was determined by the presence of SH ≥2 degree and a positive PD signal. <h3>Results</h3> We found a persistent synovitis in 23 (35.9%) of the PsA with clinical remission of the peripheral joint involvement. Active synovitis was also found in 7 (10.9%) of the patients with DAS28 &lt;2.6 which were on systemic corticosteroid (CS) treatment regimen. <h3>Conclusions</h3> The presence of active synovitis on PDUS in a significant part of the studied PsA patients (35.9%) which were considered as being in clinical remission for at least 6 months showed that these kind of patients need to be closely followed-up and adequately treated. The systemic CS treatment does not exclude the presence of disease activity in PsA. Further studies for assessment of the synovitis will establish correct criteria for defining and monitoring the disease activity in PsA. <h3>Disclosure of Interest</h3> None declared
AB0472 Impact of disease on family and social life in women with systemic lupus erythematosus (SLE)
Authors: H Babaoglu, Ö Varan, SC Guven, D Tecer, H Küçük, A Tufan, S Haznedaroglu, MA Öztürk, B Goker
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is a chronic connective tissue disease with involvement of various organ systems and characteristically has a higher incidence in women than men<sup>1</sup>. The disease, as well as its treatment, could have significant effects on the quality of life of lupus patients. <h3>Objectives</h3> Here, we aimed to investigate the impact of SLE on quality of the social and family life of women. <h3>Methods</h3> One hundred and twenty women diagnosed with SLE were included in the study. A questionnaire including questions about family and social relations were applied and demographic information, educational status, marital status, organ involvement and treatment data were obtained. The results of this study are preliminary and the study is still ongoing. <h3>Results</h3> One hundred and twenty patients were studied. The average age was 37 (± 10). 77 patients were married, 29 patients were single, 12 patients were divorced and 2 patients were widows. 29% of the patients were employed. 10,8% of the patients declared having difficulty in accepting their illnesses. 94,8% of the married patients had nuclear families. Relationship with partners and family members detoriated in 15,5% of the married patients after the diagnosis of SLE. 10,7% of single patients ended their serious relationships and 28,6% developed negative thoughts about marriage after the diagnosis of SLE. 17,6% of the married patients were exposed to verbal or physical violence by their partners. 33% of the patients declared having worse social life compared to prior to diagnosis and 20,7% declared having poor relations with their friends due to their disease. 34.5% of the patients stated that they received psychological counseling after their diagnosis. No significant relationship was found between family problems, social activities, age and educational level. <h3>Conclusions</h3> Systemic lupus erythematosus is a connective tissue disease affecting various organ systems and leading to various comorbidities. Our results suggest that family and social relations detoriate in lupus patients due to their illness independent of their age and educational level. Over one third of the patients received psychological counseling after diagnosis. Moreover, results of this study suggest that having a diagnosis of lupus has substantial impact on the marital considerations. <h3>References</h3> Hochberg, Marc C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis &amp; Rheumatology 40.9 (1997): 1725–1725. <h3>Disclosure of Interest</h3> None declared
Abstract #222: Cellular and functional heterogeneity of the sarcomatoid renal cell carcinoma cell line RCC52 with total loss of HLA class I: A system to study mesenchymal-epithelial transition
Authors: Chin-Hsuan Hsieh, Kun-Lung Chuang, Chi-Tai Yeh, Cheng-Keng Chuang, See-Tong Pang, Shuen-Kuei Liao
Journal: Cancer Research (2009)

RCC52, a cell line was established from a primary lesion of a sarcomatoid renal cell carcinoma (RCC). We have previously reported that this total loss of HLA class I was caused by the coexistence of the two mutations on the \#946;- 2  microglobulin ( \#946; 2 m ) genes. These two mutations were located in different alleles in grossly fibroblast-like and epithelioid clonal subsets, as summerized in Table below. To analysis of these sublines further, our loss of heterozygosity (LOH) results indicate that the epithelioid cells have more extensive genomic instability than the fibroblast-like cells, since the former carry one small deletion at  \#946;2m  and one large mutation (LOH) at chromosome 15, whereas the latter have two separate small mutations at  \#946;2m  with heterozygosity still maintained (ROH). The more advanced stage of epithelioid cells was supported by their faster growth rate  in vitro  and readily growth in SCID mice, as well as their predominance in the tumor lesion and in the cultured cells, compared with fibroblast-like cells. However, it is not clear whether the two morphologically distinct types of cells are two unrelated tumor subsets evolved together at the tumor site, or were in the process of a mesenchymal-epithelial transition (MET) when the disease progressed. Thus far, MET is rare compared with EMT, which has been an indication for the progression of carcinoma towards dedifferentiation and a more malignant status in other tumor types. RT-PCR analysis of the expression of Hh-associated pathway components revealed that with the exception of  Hip ,  PTCH ,  SMO ,  Ihh , and  Gli1  generally exhibited higher in epithelioid sublines. Experiments with use of this cell line are currently being conducted to determine which subset will display S100A4 with concomitant increased expression of the transcription factor Ets1. The RCC52 cell line may provide a useful model for studying the role of MET and/or EMT in tumor progression and metastasis.$$table_{358849EE-2830-4DE5-BC50-2BC48AF12C55}$$   Citation Information:  In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 222.
AB0088 The role of high mobility group box-1 (HMGB1) in inflammatory vasculopathy in collagen antibody-induced arthritis (CAIA)
Authors: F Biscetti, A Flex, F Angelini, E Gremese, B Tolusso, G Ferraccioli
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Rheumatoid arthritis (RA) is associated with vascular disease (1). Recent findings demonstrated that the risk of peripheral arterial occlusive disease is increased in patients with RA compared to the general population (2). However, the pathogenesis is not fully understood. High-mobility group box-1 (HMGB1) is a nuclear protein involved in inflammatory responses (3) and RA-like synovitis (4). <h3>Objectives</h3> Aim of the present study was to analyze the relationship between HMGB1 and peripheral arterial disease in collagen antibody-induced arthritis (CAIA). <h3>Methods</h3> BALB/c mice were injected with monoclonal anti-collagen antibody cocktail followed by lipopolysaccharide to induce arthritis. After the induction of arthritis, we studied ischemia-induced neovascularization in the ischemic hind limb of arthritic and control mice. <h3>Results</h3> We found that the perfusion recovery was significantly attenuated arthritic mice, compared to control mice. The immunohistochemical analysis for the CD31 demonstrated a reduced number of vessel in mice with experimental arthritis. The selective blockade of HMGB1 in arthritic mice resulted in restored blood flow recovery and capillary density in the ischemic muscle. Cytokine enzyme-linked immunosorbent assay (ELISA) analyses performed on peripheral blood demonstrated a significant reduction of interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α in mice where HMGB1 was blocked. Interestingly, the selective blockade of HMGB1 resulted in an increase of the peripheral IL-17A concentration. <h3>Conclusions</h3> HMGB1 pathway is involved in an experimental vasculopathy induced in a RA-like model. The proangiogenic cytokine IL-17A is increased when HMGB1 is inhibited. Although further data are needed, these findings provide new evidence regarding the pathogenesis of vascular complications observed in patients with RA. <h3>References</h3> Roman MJ, Salmon JE. Cardiovascular manifestations of rheumatologic diseases. Circulation. 2007 Nov 13;116(20):2346–55. Chuang YW, Yu MC, Lin CL, Yu TM, Shu KH, Huang ST, Kao CH. Risk of peripheral arterial occlusive disease in patients with rheumatoid arthritis. A nationwide population-based cohort study. Thromb Haemost. 2016 Jan;115(2):439–45. Biscetti F, Ghirlanda G, Flex A. Therapeutic potential of high mobility group box-1 in ischemic injury and tissue regeneration. Curr Vasc Pharmacol. 2011 Nov;9(6):677–81. Biscetti F, Flex A, Pecorini G, Angelini F, Arena V, Stigliano E, Gremese E, Tolusso B, Ferraccioli G. The role of high-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on vascular endothelial growth factor. Clin Exp Immunol. 2016 Apr;184(1):62–72. <h3>Disclosure of Interest</h3> None declared
SP0113 Pregnancy in sle: still challenging fetal and maternal issues
Authors: R Fischer-Betz
Journal: Annals of the Rheumatic Diseases (2017)

Patients with SLE are mostly young women diagnosed during their childbearing years. Several "unmet needs" in the management of reproductive health issues may impact on the decision to have children. Because of earlier recognition of disease and advances in medical treatment, family planning has gained greater importance. Concerns include the effect of pregnancy on maternal disease, the impact of disease activity on fetal health, and the safety of medications during pregnancy and breastfeeding. Preconception counselling and risk stratification (including life style, disease activity, autoantibody profile, previous vascular and pregnancy morbidity, hypertension and the use of drugs with emphasis on benefits from hydroxychloroquine and antiplatelets/anticoagulants) are essential for prevention of unwanted complications during pregnancy. Recommendations for the management of family planning and antirheumatic treatment during pregnancy and lactation have been published recently by EULAR. However, many lupus patients still do not feel that their family planning concerns are adequately addressed in current clinical practice and report that they receive inconsistent advice from the various healthcare professionals. There is a clear need for provision of up-to-date and consistent information/support to our patients. <h3>Disclosure of Interest</h3> None declared